New China Pharmaceutical 3.1 special constipation drug polycarboxylate calcium has been approved

According to the information on June 9 on the website of the State Food and Drug Administration (CFDA), the evaluation status of new China Pharmaceutical's special drug for constipation, polycarbonate, non calcium tablets and APIs, has changed to "approved - to be certified" Industry insiders expect that according to the new drug review process, Xinhua Pharmaceutical is expected to receive relevant documents within one month Xinhua Pharmaceutical is the largest production and export base of antipyretic and analgesic drugs in China In recent years, the company has increased investment in research and development from APIs to preparations Polycarbo non calcium is one of the core products currently reserved by the company, and the company pointed out on its website that the drug is expected to be listed in 2014 Polycarboxylate, a kind of 3.1-type non calcium medicine, is an innovative constipation treatment drug with dual effects of constipation and diarrhea Compared with commonly used stimulant laxatives, salt laxatives, osmotic laxatives and lubricated laxatives, Xinhua medicine pointed out that polycajaro calcium has the advantages of water retention, gelation, absorption in the body, no influence on intestinal flora, and no effect on receptors, enzymes and so on At present, only Suzhou Sinochem Pharmaceutical Industry Co., Ltd has the production approval of the drug preparation.